EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Cutaneous Adverse Events in Children Receiving Mitogen‐Activated Protein Kinase Pathway Inhibitors

Yuong Chin Tan iD, Santosh Valvi iD, Nicholas G Gottardo iD, Anne R Halbert iD

Australasian Journal of Dermatology · 2026-11 · 67 (7) · 399-405

DOI: 10.1111/ajd.70191 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 06.08.2026. Verfasst von Yuong Chin Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Dermatology, Perth Children's Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Eruptions, Protein Kinase Inhibitors, Mitogen-Activated Protein Kinases. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective Mitogen‐activated protein kinase pathway inhibitors (MAPKi) are increasingly used as targeted therapies for paediatric central nervous system tumours and other malignancies. Cutaneous toxicities, including xerosis, dermatitis, follicular‐based infections, acne, and paronychia, are common and may result in significant morbidity and treatment interruption.

Method

In this 18‐month ambispective observational cohort study, 24 consecutive children receiving MAPKi at a tertiary paediatric centre were included. Patients were followed prospectively, with retrospective data collected for those already receiving therapy at study commencement. The incidence and spectrum of cutaneous adverse events (AE), predisposing factors and management strategies were documented.

Results

Overall, 21/24 (87.5%) patients developed at least one cutaneous AE, most commonly xerosis, dermatitis, hair changes, paronychia, and pustular skin infections. Most events were Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2; however, a small number of patients required dose modification or temporary treatment interruption.

Conclusion

These findings support early dermatologic assessment and proactive management of MAPKi‐associated cutaneous toxicities. We propose practical caregiver‐directed skin care recommendations to be introduced at treatment initiation to reduce morbidity and improve treatment tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug EruptionsProtein Kinase InhibitorsMitogen-Activated Protein KinasesAdolescentChildChild, PreschoolFemaleHumansInfantMaleHair DiseasesParonychiaProspective StudiesRetrospective Studies

Stichwörter der Autor:innen

MAPK inhibitorsMEK inhibitorscutaneous toxicityneural tumourspaediatric

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Paediatric Dermatology, Perth Children's Hospital, Perth, Western Australia, Australia.
  • Department of Paediatric and Adolescent Oncology/Haematology, Perth Children's Hospital, Perth, Western Australia, Australia.

ORCID-Profile: Yuong Chin Tan, Santosh Valvi, Nicholas G Gottardo, Anne R Halbert

Zitieren

APA

Tan, Y. C., Valvi, S., Gottardo, N. G., & Halbert, A. R. (2026). Cutaneous Adverse Events in Children Receiving Mitogen‐Activated Protein Kinase Pathway Inhibitors. Australasian Journal of Dermatology, 67(7), 399-405. https://doi.org/10.1111/ajd.70191

Vancouver

Tan YC, Valvi S, Gottardo NG, Halbert AR. Cutaneous Adverse Events in Children Receiving Mitogen‐Activated Protein Kinase Pathway Inhibitors. Australasian Journal of Dermatology. 2026;67(7):399-405. doi:10.1111/ajd.70191

BibTeX
@article{Tan2026,
  author = {Tan, Yuong Chin and Valvi, Santosh and Gottardo, Nicholas G and Halbert, Anne R},
  title = {Cutaneous Adverse Events in Children Receiving Mitogen‐Activated Protein Kinase Pathway Inhibitors},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  volume = {67},
  number = {7},
  pages = {399--405},
  doi = {10.1111/ajd.70191}
}
Kostenlos starten →